Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Helping Stroke Patients With ThermoSuit Cooling
NCT02453373 · Life Recovery Systems · NA · terminated · last registry update 2023-06-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has achieved its objectives of showing feasibility, safety, and trend for improved mRS. FDA and LRS agreed that this study should be terminated, and that a new, PIVOTAL trial should be started.” | – | Registry record, Life Recovery Systems |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-22Results posted on the registry: Genentech, Inc., Tenecteplase (NCT03785678)
- 2024-04-09Also stopped (withdrawn): Zeenat Qureshi Stroke Institute, Reteplase Injection (NCT05900674)
- 2024-04-08Phase 3 first posted: The George Institute, Standard-dose intravenous tenecteplase + Low-dose intravenous tenecteplase (NCT06352632)
- 2024-03-20Phase 3 first posted: University of Calgary, Tenecteplase (NCT06320431)
- 2024-03-07Results posted on the registry: Boehringer Ingelheim, Alteplase low dose + Alteplase high dose (NCT04640194)
- 2024-02-20Results posted on the registry: University of Florida, tPA + DNase (NCT03213834)
- 2024-02-08Also stopped (withdrawn): Azienda U.S.L. 1 di Massa e Carrara, Alteplase (NCT02604238)
- 2024-01-24Phase 3 first posted: Beijing Tiantan Hospital, Tenecteplase (NCT06221371)
- 2024-01-09Phase 3 first posted: Beijing Tiantan Hospital, Tenecteplase + Best Practice (which may include intravenous Alteplase) (NCT06196320)
- 2023-12-05Also stopped (terminated): University Hospital Heidelberg, a drug against PLAT (NCT03094715)
- 2023-11-01Results posted on the registry: University of Michigan, Treatment-inhaled tPA (NCT02315898)
- 2023-07-28Phase 3 first posted: Ji Xunming,MD,PhD, Intravenous thrombolysis(rt-PA) (NCT05965687)
- 2023-07-28Phase 3 first posted: Ji Xunming,MD,PhD, Intravenous thrombolysis(rt-PA) (NCT05965193)
- 2023-05-12Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Alteplase (NCT05856851)
- 2023-04-26Results posted on the registry: Boehringer Ingelheim, Alteplase (from modified manufacturing process) + Alteplase (from current manufacturing process) (NCT04419493)
- 2023-04-24Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, Intravenous thrombolysis (NCT05827042)
- 2023-04-20Results posted on the registry: Thrombolex, Inc., r-tPA (NCT04248868)
- 2023-04-06Results posted on the registry: Hooman Poor, Tenecteplase + Placebo (NCT04505592)
- 2023-04-04Phase 3 first posted: Hospital Clinic of Barcelona, Intraarterial alteplase (NCT05797792)
- 2023-03-30Results posted on the registry: Thrombolex, Inc., r-tPA (NCT03927508)
- 2023-03-23Also stopped (withdrawn): Universitaire Ziekenhuizen KU Leuven, Intravenous Infusion (NCT03417401)
- 2023-03-13Phase 3 first posted: Chinese University of Hong Kong, Tissue Plasminogen Activator (NCT05766124)
- 2023-02-27Phase 3 first posted: Beijing Tiantan Hospital, Alteplase + Tenecteplase (NCT05745259)
- 2023-01-27Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, Tenecteplase (NCT05701956)
- 2023-01-26Phase 3 first posted: Tasly Biopharmaceuticals Co., Ltd., rhPro-UK + rt-PA (NCT05700591)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision